Drug
CLR 131
CLR 131 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
active_not_recruiting267%
completed133%
Recent Activity
2 active trials
Showing 3 of 3
active_not_recruitingphase_1
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
NCT03478462
active_not_recruitingphase_1
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
NCT05610891
completedphase_1
CLR 131 Combined With Radiation for Head and Neck Cancer
NCT04105543
Clinical Trials (3)
Showing 3 of 3 trials
NCT03478462Phase 1
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
NCT05610891Phase 1
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
NCT04105543Phase 1
CLR 131 Combined With Radiation for Head and Neck Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3